Clinical Trials

30 enrolled

Triple Negative Breast Neoplasms

NCT05763199 2026-03-12

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Phase NA Active not recruiting

20 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

81 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT05710328 2026-03-02

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

235 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT04928807 2026-02-27

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

231 enrolled

Rectal Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase EARLY_PHASE1 Active not recruiting

327 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

15 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07429318 2026-02-24

GC/GEJC

Active not recruiting

300 enrolled

Phase 1/2 Active not recruiting

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 1 Active not recruiting

855 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05421897 2026-01-29

RAPID

11 enrolled

CNS

Neoplasms, Neuroblastoma

NCT03210103 2026-01-28

ORATOR2

Phase NA Active not recruiting

61 enrolled

Head & Neck

Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT07339488 2026-01-14

ILDR-03

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Phase NA Active not recruiting

Breast Neoplasms

NCT02454543 2026-01-12

g-RAMPP

452 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03599752 2026-01-09

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

40 enrolled

Colorectal Neoplasms

NCT03570892 2026-01-06

BELINDA

331 enrolled 10 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07306663 2025-12-29

ESO-Nanjing7

242 enrolled

Esophageal Neoplasms

NCT02153229 2025-12-26

MPM-PDT